fulvene-5

inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice; structure in first source

Networked: 4 relevant articles (1 outcomes, 0 trials/studies)

1.	Arbiser, Jack L: 3 articles (01/2018 - 08/2009)
2.	Bonner, Michael Y: 2 articles (02/2015 - 08/2009)
3.	Grdina, David J: 1 article (01/2018)
4.	Murley, Jeffrey S: 1 article (01/2018)
5.	Weichselbaum, Ralph R: 1 article (01/2018)
6.	Aziz, Towqir: 1 article (02/2015)
7.	Bonner, William M: 1 article (02/2015)
8.	Choudhuri, Rohini: 1 article (02/2015)
9.	Maeda, Daisuke: 1 article (02/2015)
10.	Parekh, Palak R: 1 article (02/2015)

1.	Hypertension (High Blood Pressure) 10/01/2013 - "Together, these findings indicate that Fulvene-5, and perhaps other classes of antioxidant inhibitors, may represent a novel class of compounds useful for the treatment of pathological disorders stemming from inappropriate ion channel activity, such as hypertension."
2.	Neoplasms (Cancer) 02/17/2015 - "Injecting Atm-null mice with fulvene-5, a specific inhibitor of NOX4 and NADPH oxidase 2 (NOX2), decreased their elevated cancer incidence to that of the controls. " 08/01/2009 - "Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice."
3.	Hemangioma (Angioma) 08/01/2009 - "We therefore produced and began the initial characterization of fulvenes as potential Nox inhibitors, finding that fulvene-5 efficiently inhibited Nox activity in vitro and potently inhibited hemangioma growth in vivo. "
4.	Carcinoma (Carcinomatosis) 01/01/2018 - "Utilizing human colon carcinoma HCT116 TP53 wild type (WT) and HCT116 isogenic TP53 null mutant (Mut) cell cultures, the roles of inter- and intracellular ROS signaling on expression of the adaptive response as evidenced by changes in intracellular translocation of survivin measured by ELISA, and cell survival determined by a standard colony forming assay were investigated using ROS modifying agents that include emodin, N-acetyl-L-cysteine (NAC), fulvene-5, honokiol, metformin and rotenone. "